TABLE 2.
Glycaemic control and insulin therapy during hospital admission
| Glycaemic control | Placebo | Sitagliptin | P-value |
|---|---|---|---|
| Admission HbA1c, % | 7.7 ± 1.7 | 7.4 ± 1.3 | .18 |
| Randomization BG, mmol/L | 8.9 ± 3.3 | 8.8 ± 3.5 | .55 |
| Admission BG, mmol/L | 9.2 ± 3.7 | 8.7 ± 3.0 | .38 |
| Preoperative BG, mmol/L | 8.6 ± 2.3 | 8.4 ± 2.7 | .15 |
| Postoperative BG, mmol/L | 8.7 ± 2.0 | 8.6 ± 1.6 | .93 |
| BG during surgery, mmol/L | 9.2 ± 1.6 | 9.0 ± 1.7 | .44 |
| BG during ICU stay, mmol/L | 8.2 ± 0.9 | 8.2 ± 0.9 | .64 |
| BG after transition, mmol/L | 9.2 ± 1.7 | 9.3 ± 1.7 | .94 |
| Hyperglycaemia BG > 10 mmol/L (>180 mg/dL) | |||
| Participants with BG >10 mmol/L in OR | 60 (67) | 56 (61) | .42 |
| Participants with BG >10 mmol/L in the ICU | 76 (84) | 68 (75) | .14 |
| Participants with BG >10 mmol/L after transition | 76 (88) | 72 (83) | .39 |
| Hyperglycaemia BG > 111 mmol/L (>200 mg/dL) | |||
| Participants with BG >111 mmol/L in OR | 36 (40) | 36 (39) | .90 |
| Participants with BG >111 mmol/L in the ICU | 46 (51) | 49 (54) | .66 |
| Participants with BG >111 mmol/L after transition | 66 (77) | 63 (72) | .51 |
| Hypoglycaemia BG < 3 9 mmol/L (<70 mg/dL) | |||
| Participant with BG <3 9 mmol/L in OR | 0(0) | 0(0) | - |
| Participants with BG <3 9 mmol/L in the ICU | 8 (9) | 9 (10) | >.99 |
| Participants with BG <3 9 mmol/L after transition | 8 (9) | 8(9) | >.99 |
| Hypoglycaemia BG < 3 0 mmol/L (<54 mg/dL) | |||
| Participants with BG <3 0 mmol/L in OR | 0 (0) | 0 (0) | - |
| Participants with BG <3 0 mmol/L in the ICU | 1 (1) | 4 (4) | .37 |
| Participants with BG <3 0 mmol/L after transition | 0 (0) | 3 (3) | .25 |
| Hypoglycaemia BG < 2 2 mmol/L (<40 mg/dL) | |||
| Participants with BG <2 2 mmol/L in OR | 0 (0) | 0 (0) | - |
| Participants with BG <2 2 mmol/L in the ICU | 0 (0) | 1 (1) | >.99 |
| Participants with BG <2 2 mmol/L after transition | 0 (0) | 0 (0) | - |
| Insulin therapy | |||
| Participants treated with CII in OR | 76 (84) | 74 (80) | .48 |
| Duration of CII in OR, hours | 3.3 ± 2.2 | 3.4 ± 2.5 | .53 |
| Total insulin dose in OR, units | 13.2 ± 13.1 | 14.1 ± 16.1 | .97 |
| Participants treated with CII in ICU | 86 (95) | 85 (93) | >.99 |
| Duration of CII, hours (ICU first 48 hours) | 21.4 ± 13.9 | 22.0 ± 14.3 | .77 |
| Total insulin dose in the ICU (first 48 hours), units | 73.7 ± 69.9 | 80.4 ± 79.8 | .48 |
| Participants treated with SC basal bolus regimen after discontinuation of CII | 78 (91) | 74 (85) | .35 |
Abbreviations: BG, blood glucose; CII, continuous insulin infusion; ICU, intensive care unit; LOS, length of stay; OR, operating room; SC, subcutaneous; SSI, sliding scale insulin.
Data are n (%), mean ± standard deviation, or median [IQR]; IQR, interquartile range.
To convert HbA1c value in % to mmol/mol = 10.93 × %HbA1c value −23.5), BG value in mg/dL to mmol/L = BG mg/dL value/18.